Imaging Response to Ensartinib in Concurrent Papillary and Anaplastic Thyroid Carcinoma With ALK Rearrangement.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 42149625.
- Also identified by DOI 10.1097/RLU.0000000000006437.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 67-year-old woman with coexisting papillary thyroid carcinoma (PTC) and anaplastic thyroid carcinoma (ATC) harbored an ALK rearrangement on FISH. Despite surgery and 2 courses of 131 I treatments, 18 F-FDG PET/CT showed an intensely avid right lower-neck mass extending into the superior mediastinum. The patient was considered radioiodine-refractory (RAIR) and started ensartinib (225 mg once daily). CT at 3 months showed marked regression, with sustained disease control at 12 months. This case illustrates an objective imaging response to ALK-directed therapy in RAIR thyroid carcinoma.
Medical subject headings
- Thyroid Carcinoma, Anaplastic
- Thyroid Neoplasms
- Receptor Protein-Tyrosine Kinases
- Positron Emission Tomography Computed Tomography
- Gene Rearrangement